Left ventricular dilatation and failure post-myocardial infarction: Pathophysiology and possible pharmacologic interventions
Autor: | Brian G. Firth, Preston M. Dunnmon |
---|---|
Rok vydání: | 1990 |
Předmět: |
medicine.medical_specialty
medicine.medical_treatment Myocardial Infarction Cardiomegaly Ventricular Function Left Muscle hypertrophy Internal medicine Renin–angiotensin system medicine Animals Humans Pharmacology (medical) cardiovascular diseases Myocardial infarction Heart Failure Pharmacology Chemotherapy biology business.industry Angiotensin-converting enzyme Captopril General Medicine medicine.disease Pathophysiology Disease Models Animal Heart failure cardiovascular system biology.protein Cardiology Cardiology and Cardiovascular Medicine business Dilatation Pathologic medicine.drug |
Zdroj: | Cardiovascular Drugs and Therapy. 4:1363-1374 |
ISSN: | 1573-7241 0920-3206 |
DOI: | 10.1007/bf02018264 |
Popis: | An important antecedent to the development of late congestive heart failure is left ventricular dilatation and remodeling following myocardial infarction, which occurs in 30-40% of acute anterior transmural infarcts. Dilatation and remodeling commence within the first 24 hours following myocardial infarction and may be steadily progressive over months to years. Both the infarcted and uninfarcted regions of the myocardium are equally involved in the process. The remodeling process comprises left ventricular wall thinning (mainly due to cell slippage), chamber dilatation, and compensatory hypertrophy of the uninfarcted segment of the myocardium. The hypertrophy may initially be physiologic but may ultimately become a pathologic process, and thereby contribute to pump dysfunction. The possible reasons why the ventricular hypertrophy may ultimately be dysfunctional include alterations in local architecture and their sequelae alone or in concert with local changes in the beta-adrenergic, alpha-adrenergic, or renin angiotensin systems. At the present time, there are encouraging data to suggest that nitroglycerin, or the angiotensin converting enzyme inhibitor captopril, may ameliorate this process. |
Databáze: | OpenAIRE |
Externí odkaz: |